Stock Taper
SCREENER COMPARE ANY 2 STOCKS
QURE
UNIQURE N.V.
NASDAQ
$48.72
▼ DOWN 1.69% (-0.84)

KEY STATISTICS

Market Cap$3.38 B
52w High$71.50
52w Low$8.73
Dividend Yield—
Frequency—
P/E-12.15
Volume843.55K
Shares Out.69.37M

COMPANY

LEADERSHIP

Matthew Craig Kapusta
CHIEF EXECUTIVE
Matthew Craig Kapusta

COMPENSATION 2026

Salary$676,170
Stock Awards$1,079,100
Incentive Plan Pay$345,117
All Other Comp.$1,516
Total$3,287,434

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 5, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
221

PRICE TARGET

Target High$80.00
Target Low$28.00
Target Median$60.50
Target Consensus$57.50

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$6.21M
NOV
9
MON

PRICE

$48.72 ▼ DOWN 1.69% (−$0.84)
$48.60$48.90$49.20$49.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM48.72

About uniQure N.V.

https://www.uniqure.com ↗

uniQure N.V. is a gene therapy company developing treatments for genetic and devastating diseases, with lead programs in hemophilia B, Huntington's disease, Parkinson's, epilepsy, Alzheimer's, and ALS.

INDUSTRY

Biotechnology

A PRODUCT UNIQURE N.V. IS KNOWN FOR

HEMGENIX® (etranacogene dezaparvovec-drlb)
HEMGENIX® (etranacogene dezaparvovec-drlb)

HEMGENIX® is the first FDA-approved one-time gene therapy for adults with Hemophilia B, developed and manufactured by uniQure, with exclusive global commercialization rights licensed to CSL Behring.

COMPETITORS

COMPETITOR
BMRN COMPARE
CRSP COMPARE
RARE COMPARE
SG SGMO COMPARE
SRPT COMPARE

Revenue by Products

IconPRODUCTQ1-2025Q2-2025Q3-2025Q4-2025
License revenues$1.57M $5.26M ▲$3.58M ▼$5.52M ▲
Collaboration revenues— — $119K $45K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
39
LISTED HERE
13
RANKED BY POSITION SIZE
XBI
1.06% · 2.6M
VXF
0.04% · 783.5K
SCHA
0.07% · 322.5K
FYC
0.56% · 164.9K
LABU
0.72% · 92.6K
XUU.TO
0.00% · 89.4K
PTH
1.56% · 88.6K
GNOM
2.05% · 39.5K
BBC
1.08% · 11.4K
WDNA.L
1.18% · 7.8K
BIB
0.11% · 2.3K
AI
AIIQ
0.52% · 1.8K
VETS
0.10% · 1.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
66.01%
HOLDERS
402
TOP 12 OF 402 · RANKED BY POSITION SIZE
Avoro Capital Advisors LLC
6.7M sh · $309.88M
Fmr LLC
6.2M sh · $149.35M
Abrdn Plc
5.3M sh · $86.76M
Jpmorgan Chase & Co
4.9M sh · $230.81M
Rtw Investments, LP
4.4M sh · $258.29M
Ecor1 Capital, LLC
4.0M sh · $232.84M
State Street Corp
3.2M sh · $77.32M
Two Sigma Investments, LP
2.7M sh · $43.75M
Boxer Capital, LLC
2.2M sh · $10.97M
Orbimed Advisors LLC
2.1M sh · $34.93M
Franklin Resources Inc
2.0M sh · $116.07M
Blackrock, Inc.
2.0M sh · $47.26M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR, OFFICER: CEO, MANAGING DIRECTOR
Kapusta Matthew C
Purchase · 21.1K shares
2026-07-02
★
DIRECTOR, OFFICER: CEO, MANAGING DIRECTOR
Kapusta Matthew C
Sale · 9.2K shares
2026-07-02
★
DIRECTOR, OFFICER: CEO, MANAGING DIRECTOR
Kapusta Matthew C
Sale · 4.3K shares
2026-07-02
★
DIRECTOR, OFFICER: CEO, MANAGING DIRECTOR
Kapusta Matthew C
Sale · 7.6K shares
2026-07-02

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 4
BUY 4
OVERWEIGHT 2
NEUTRAL 2
MARKET PERFORM 1
13 GRADES IN THE LAST 12 MONTHS
Barclays OVERWEIGHT Wells Fargo OVERWEIGHT Wolfe Research OUTPERFORM HC Wainwright & Co. BUY Mizuho OUTPERFORM Goldman Sachs NEUTRAL Leerink Partners OUTPERFORM RBC Capital OUTPERFORM

SECTORS PEERS

PEERPRICE
EWTX$42.76COMPARE
ABCL$11.35COMPARE
GPCR$47.37COMPARE
VRDN$23.08COMPARE
CLDX$39.12COMPARE
VERA$34.19COMPARE
NUVB$6.66COMPARE
OCUL$10.36COMPARE